Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Three Bioscience Breakthroughs You Can't Afford to Miss

You can make huge gains investing in a breakthrough drug, but you can do even better putting your money into a new, cutting-edge technology platform that can fuel a company's entire pipeline.

One biotech I recommended to my BioScience Millionaire subscribers last July, Sangamo Biosciences Inc. (Nasdaq: SGMO), has developed a technology from naturally occurring molecules, called zinc finger proteins (ZFPs), that scientists can engineer to edit specific genes in the human genome. It can cut them out, replace them, or add new ones – in other words, it plays with the basic building blocks of life as if they were Lego pieces!

Sangamo is currently using ZFP technology to find cures for some of the most intractable – and often un-druggable – diseases we know of, including HIV, Alzheimer's, Huntington's, and Down's syndrome to name a few.

And Sangamo isn't the only company using ZFPs for research. In fact, it licenses out the technology to scientific institutions and companies all over the world – providing it with a great revenue stream.

As a result, SGMO shares have gone up more than 150% since last summer. Actually, if you'd had the foresight to buy the stock at the beginning of 2012, you'd now be realizing profits of 577% on your money.

The magic word in that sentence is "foresight." The trick is to spot these technologies early in their development, either before they've had IPOs or soon after.

With that in mind, here are a few exciting new technologies to keep an eye on…

Breakthrough No. 1

Amazing Work with Genes

Last year I had the privilege of being the only bioscience writer to attend a privately held international conference in New York City on inflammatory bowel disease. One hundred of the top researchers in the world were there, and one of them, a scientist from Harvard, specifically mentioned ZFPs (see above) as central to his work. He also mentioned a similar gene editing tool called TALENS. But the really exciting one, which he spoke about in passing, is called CRISPR.

CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. I know. Don't ask. The explanation is as long, complex, and sleep-inducing as you might suspect.

But the short version is this: ZFP and TALENS use proteins to do their gene editing, and proteins are – in the sub-microscopic world – big and unwieldy. It's very hard to manipulate them to produce the mass quantities of re-sculpted genes you would need to treat some diseases.

CRISPR, on the other hand, uses very small bits of RNA (ribonucleic acid, a chemical present in all living cells) to achieve the same ends, and comparing it to ZFP and TALENS is like comparing a scalpel to a hatchet. It is fast, precise, and can produce edited genes en mass.

Over the past year, CRISPR has been showing up in labs all over the world and has turned into a tech platform for several new biotechs. Sangamo need not worry – ZFPs and TALENS will always have a secure place in research, because CRISPR does have some limitations, but it's likely to dwarf their success.

Join the conversation. Click here to jump to comments…

About the Author

Ernie Tremblay has more than 25 years of experience in following and analyzing the latest developments in health, medicine, and related technologies. He understands the FDA approval process, as well as the "hard science" behind new, experimental drugs and the market demand for them - and has a comprehensive grasp of the complex dynamics that determine whether a new drug will be a breakthrough winner, or just another casualty of the FDA approval process.

Read full bio

  1. yngso | March 1, 2014

    Thak you, but I have a question: Is it possible to give us what you shared with your paying customers sooner? Maybe that way you would attract more paying customers?

  2. Ernie Tremblay | March 4, 2014

    Good question, and thanks for your interest. My subscribers pay a substantial premium to receive my exclusive recommendations and trading instructions, including when to buy, at what level, and when to take profits. I can't make that information generally available. It just wouldn’t be fair to them. But beyond that, these can be very fast-moving stocks with a lot of firepower behind them. My recommendations are generally connected to regulatory “catalysts” — data releases, FDA advisory committees, CDER decisions, etc. — so even if I could share that information, the profits may already be baked in by the time you get it.

    But I do have something special coming for readers like you…

    I’m working on a specific bioscience recommendation for Money Morning readers. I find this stock very interesting for its long-term potential, and I think you will too. Please stay tuned for that in the next couple weeks.

  3. Andrew | March 5, 2014

    Greetings good sir, so I was listening to sgmo's conference today and they said in two days there embargoes data will be released on HIV, does that basically mean they have a functional cure and there just building up hyper, or "just building up hype" for stock prices, thank you

    • Ernie Tremblay | March 7, 2014

      Hi, Andrew. Sangamo (SGMO) has a great technology that allows them to do some amazing things at the genetic level. What they're doing with HIV is artificially reproducing the protective proteins of people who are naturally immune to the virus. Their hurdle is to make enough of these proteins to be effective in an individual. My sense is that they're well on their way to achieving their goal, but it will be some time before a drug, that is, a functional cure, comes to market. I expect the data release to be positive and stock valuation to be strong.

Leave a Reply

Your email address will not be published. Required fields are marked *


Some HTML is OK